Daiichi initiates arbitration proceedings against Singhs of Ranbaxy but is it more symbolic?
This article was originally published in Scrip
Executive Summary
Following through on its May 22 statement, Daiichi Sankyo is said to have moved towards initiating arbitration proceedings in Singapore against the former shareholders of Ranbaxy Laboratories, the Singh brothers, over alleged misrepresentation of critical information concerning the US Department of Justice (DoJ) and FDA investigations against Ranbaxy at the time of the 2008 takeover by the Japanese company.